

AMYPAD Deliverable 3.15

Mid-term recruitment report

Quarterly report V8

Publishable Summary

The last quarter of 2020 has been a very important step in the DPMS advancement. The recruitment had to be completed while all sites were dealing with their local COVID-19-related constraints.

After different measures taken, and an in-depth analysis of the situation, it has been decided to discontinue the patient's inclusion in the study at the end of October 2020.

At this date, 844 patients on 900 planned were included, representing 94% of the initial target, a great achievement in this situation. With the decision to stop including patients, sites have now the possibility to focus on two main goals:

- Perform all the remaining protocol visits and scans for patients still in the study, while dealing with a still uncertain situation.
- Proceed with the database cleaning tasks to provide a clean dataset for analysis.

To date, all the baseline eCRF have been checked and 95% of them have been corrected, and this allowed the team to start working on the description of the baseline features of the patients enrolled so far.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

